Head to head
Wolverine blend against KLOW blend
Two vendor blends for the same purpose, one with two components and one with four. Neither combination has been studied in any species, and the larger blend is dominated by mass by a single ingredient, which makes its dosing arithmetic the most useful thing to understand about it.
Column A
Wolverine blendWolverine (BPC-157 + TB-500)
Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the combination. BPC-157's systematic review found 36 studies of which 35 were preclinical, and what vendors sell as TB-500 is not thymosin beta 4 but a seven amino acid fragment of it.
Column B
KLOW blendKLOW (GHK-Cu + KPV + BPC-157 + TB-500)
A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation. No study has tested the combination in any species. GHK-Cu is 62.5% of the powder, so the vial carries roughly 7.9 mg of elemental copper and anyone dosing KLOW by units is mostly dosing a copper peptide.
Side by side, on the facts we can check
| Attribute | Wolverine blend | KLOW blend |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not approved, and the combination has never been evaluated. FDA staff reviewed BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee meeting and found no adequate human data along with mislabelled products in the market. Neither component is an approved medicine anywhere. | Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market. |
| Half-life | Not defined for the blend, and the components differ. A systematic review reports BPC-157 as hepatically metabolised with a half-life under 30 minutes and renal clearance. | Not defined for the blend, and the components differ. No pharmacokinetic study of the mixture exists. |
| Molecular weight | A mixture. BPC-157 is about 1,419 Da. The Ac-LKKTETQ fragment identified in TB-500 is about 861 Da, well short of the roughly 4,960 Da of full-length thymosin beta 4. | A mixture. GHK-Cu is about 403 Da as the copper complex, KPV 342.4 Da, BPC-157 1,419.5 Da, and the Ac-LKKTETQ fragment sold as TB-500 about 889 Da. |
| Mechanism | Assumed additive, and assumed is the operative word. BPC-157 is reported in preclinical models to raise growth hormone receptor expression and several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines. The thymosin beta 4 parent protein sequesters G-actin and promotes cell migration, and the Ac-LKKTETQ fragment that TB-500 actually contains sits within the actin-binding region. No paper describes what happens when the two are given together, whether their effects are additive, redundant or interfering, or whether the two peptides are stable in one vial. | Assumed to be the sum of the parts, and assumed is the operative word. GHK-Cu carries copper into tissue and has been shown in culture and in rat wound chambers to drive collagen and glycosaminoglycan production. KPV is the C-terminal tripeptide of alpha-MSH and blocks NF-kB and MAP kinase signalling in intestinal epithelial and immune cells. BPC-157 and TB-500 act through the tissue-repair pathways described on their own pages. No paper describes what these four do in the same syringe, whether the effects add, overlap or interfere, or whether an acidic copper complex is compatible in solution with three other peptides over the weeks a vial stays in a fridge. |
| Human studies cited | 1 | 2 |
| Legal status, US | Not approved; research use only | Not approved; sold 'for research use only' |
Frequently asked questions
What is the difference between Wolverine blend and KLOW blend?
Wolverine blend: Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the combination. BPC-157's systematic review found 36 studies of which 35 were preclinical, and what vendors sell as TB-500 is not thymosin beta 4 but a seven amino acid fragment of it. KLOW blend: A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation. No study has tested the combination in any species. GHK-Cu is 62.5% of the powder, so the vial carries roughly 7.9 mg of elemental copper and anyone dosing KLOW by units is mostly dosing a copper peptide.
Which has stronger research evidence, Wolverine blend or KLOW blend?
This database does not grade compounds. It counts what was run in people: 1 of the 8 studies cited on the Wolverine blend profile were human work, against 2 of 10 for KLOW blend. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Wolverine blend and KLOW blend FDA-approved?
Wolverine blend: Not approved, and the combination has never been evaluated. FDA staff reviewed BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee meeting and found no adequate human data along with mislabelled products in the market. Neither component is an approved medicine anywhere.. KLOW blend: Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market..
Related posts
Blog articles that cover Wolverine blend or KLOW blend, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.